Andrew Obenshain, bluebird bio CEO

Blue­bird is still look­ing for more fi­nanc­ing as it brings sick­le cell ther­a­py to mar­ket: #JPM24

SAN FRAN­CIS­CO — Af­ter strik­ing deals for as much as $225 mil­lion in fi­nanc­ing, blue­bird bio’s CEO said the com­pa­ny is still on the look­out for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.